These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 22670305)

  • 21. [New oral anticoagulants for atrial fibrillation: a neurologist's view].
    van Dijk EJ; Koudstaal PJ; Roos YB; Brouwers PJ; Kappelle LJ
    Ned Tijdschr Geneeskd; 2012; 156(39):A5283. PubMed ID: 23009824
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lack of stroke subtype information may hinder indirect comparison between the ROCKET-AF and other trials of new oral anticoagulants.
    Li HF; Zhao RL
    J Am Coll Cardiol; 2013 Feb; 61(5):595-6. PubMed ID: 23273400
    [No Abstract]   [Full Text] [Related]  

  • 23. New anticoagulants for the prevention of deep venous thrombosis: time to consider cost effectiveness?
    Apostolakis S; Shantsila E; Lip GY
    Pharmacoeconomics; 2009; 27(10):793-5. PubMed ID: 19803535
    [No Abstract]   [Full Text] [Related]  

  • 24. Reply: To PMID 22575324.
    Lip GY; Larsen TB; Skjøth F; Rasmussen LH
    J Am Coll Cardiol; 2013 Feb; 61(5):596. PubMed ID: 23273397
    [No Abstract]   [Full Text] [Related]  

  • 25. Dabigatran etexilate: a possible replacement for heparinoids and vitamin K antagonists?
    Guay DR
    Hosp Pract (1995); 2011 Feb; 39(1):105-25. PubMed ID: 21441766
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dabigatran for stroke prevention in atrial fibrillation: the RE-LY trial.
    Paikin JS; Haroun MJ; Eikelboom JW
    Expert Rev Cardiovasc Ther; 2011 Mar; 9(3):279-86. PubMed ID: 21438804
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A review of oral anticoagulants in patients with atrial fibrillation.
    Greenspon AJ
    Postgrad Med; 2012 Nov; 124(6):7-16. PubMed ID: 23322134
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of orally available antagonists of factor Xa in the treatment and prevention of thromboembolic disease: focus on rivaroxaban.
    Morell J; Sullivan B; Khalabuda M; McBride BF
    J Clin Pharmacol; 2010 Sep; 50(9):986-1000. PubMed ID: 20124518
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical management of the new anticoagulants].
    Zapata Wainberg G; Ximénez-Carrillo Rico A; Vivancos Mora J
    Neurologia; 2012 Mar; 27 Suppl 1():33-8. PubMed ID: 22682208
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Pradaxa: more advantageous than warfarin?].
    Sabourin G
    Perspect Infirm; 2013; 10(1):58. PubMed ID: 23379052
    [No Abstract]   [Full Text] [Related]  

  • 31. Insights from the dabigatran versus warfarin in patients with atrial fibrillation (RE-LY) trial.
    Khoo CW; Lip GY
    Expert Opin Pharmacother; 2010 Mar; 11(4):685-7. PubMed ID: 20105114
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New oral anticoagulants.
    Sun D; Lazo-Langner A
    CMAJ; 2013 Mar; 185(4):E212. PubMed ID: 23148053
    [No Abstract]   [Full Text] [Related]  

  • 33. [Prevention and therapy of thromboembolism: rivaroxaban - better outcome - risk profile as standard therapy].
    MMW Fortschr Med; 2013 Sep; 155(15):56-7. PubMed ID: 24224377
    [No Abstract]   [Full Text] [Related]  

  • 34. [New anticoagulants: better knowledge, better prescriptions].
    Boehlen F; de Moerloose P
    Rev Med Suisse; 2012 Jan; 8(324):96-9. PubMed ID: 23185817
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dabigatran etexilate (Pradaxa) for the treatment of atrial fibrillation.
    Belavic JM
    Nurse Pract; 2011 Sep; 36(9):6-7. PubMed ID: 21857210
    [No Abstract]   [Full Text] [Related]  

  • 36. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
    Mantha S; Ansell J
    Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rivaroxaban for stroke prevention in atrial fibrillation: a critical review of the ROCKET AF trial.
    Paikin JS; Manolakos JJ; Eikelboom JW
    Expert Rev Cardiovasc Ther; 2012 Aug; 10(8):965-72. PubMed ID: 23030284
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].
    Dumont B; Faille D; Ajzenberg N
    Med Sci (Paris); 2011 May; 27(5):493-500. PubMed ID: 21609670
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Expanded arsenal in atrial fibrillation: bye-bye marcumar?].
    MMW Fortschr Med; 2012 Jan; 154(1):20. PubMed ID: 22641998
    [No Abstract]   [Full Text] [Related]  

  • 40. Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of clinical data.
    Ma TK; Yan BP; Lam YY
    Pharmacol Ther; 2011 Feb; 129(2):185-94. PubMed ID: 20920530
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.